Global Acute Myeloid Leukemia Market This market research provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Research classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%.
The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
Avail a Sample Copy before Purchase:
The American Cancer Societys estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. This statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.
Market competition by Top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the Top players including-
Celegene Corporation, Novartis AG, Genmab AS, Eisai Co. Ltd, Sanofi-Aventis (Genzyme Corporation), Teva Pharmaceutical (Cephalon Inc.), Pfizer Inc., Bristol-Myers Squibb Company, Sunesis Pharmaceuticals Inc.
Scope Of The Report
Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.
Key Market Trends-
Cytarabine is Expected to hold its Highest Market Share in the Chemotherapy Segment
In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.
Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin’s lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
Get Exclusive Discount at-
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.
Major points covered in this research are:-
- Acute Myeloid Leukemia Market Overview, Segment by Type (Product Category), by Application, by Region (2019-2024), Competition by Manufacturers
- Global Market Size (Value) of Acute Myeloid Leukemia (2019-2024)
- Global Acute Myeloid Leukemia Capacity, Production, Revenue (Value), Supply (Production), Consumption, Export, Import by Region (2019-2015)
- Global Acute Myeloid Leukemia Production, Revenue (Value), Price Trend by Type
- Global Acute Myeloid Leukemia Market Analysis by Application
- Global Acute Myeloid Leukemia Manufacturers Profiles/Analysis
- Acute Myeloid Leukemia Manufacturing Cost Analysis
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Marketing Strategy Analysis, Distributors/Traders
- Market Effect Factors Analysis
- Global Acute Myeloid Leukemia Market Forecast (2019-2024)
- Competitive Landscape
- Research Findings and Conclusion
Buy Now This Report at
Finally, this Acute Myeloid Leukemia report covers the market scenario and its development prospects over the coming years. Report likewise manages the type analysis, contrasting it with the significant application, recent Acute Myeloid Leukemia product development and gives an outline of the potential Global market.
Irfan Tamboli (Sales)
Phone: + 1704 266 3234